LIVE: FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meets on Biologics License for Deramiocel

The FDA Cellular, Tissue, and Gene Therapies Advisory Committee meets at 9:30 a.m. ET on July 29 to discuss and make recommendations on Biologics License Application 125842 from Capricor, Inc. for Deramiocel (human allogeneic cardiosphere-derived cells) in the treatment of cardiomyopathy in Duchenne muscular dystrophy.
Video Summary
AI GeneratedThis FDA advisory committee meeting reviewed the Biologics License Application for daramia cell (also referred to as Teramaricil/Dermyocell), an allogeneic cellular therapy intended to treat cardiomyopathy in patients with Duchenne muscular dystrophy (DMD). Despite powerful patient testimonies and claims of stabilized cardiac and upper limb function, the committee ultimately voted against approval, citing fragile statistical data and a failure to meet primary endpoints.
